Dominant Negative TGF-β Receptor Type II in T Lymphocytes Promotes Anti-tumor Immunity by Modulating T Cell Subsets and Enhancing CTL Responses

Investigators demonstrated that dominant negative TGF-β receptor type II specifically targeting T cells decreased tumor load in tumor-bearing mice.